Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DW6014 vs Loose Combination of Empagliflozin and Metformin in Healthy Volunteers
NCT05823883Phase 1Unknown
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW6014 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve from time zero to last quantifiable concentration at 48 hour and Maximum Plasma Concentration at 48 hour. Status: unknown.
02
Drugs
DW6014
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05823883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823883.